Skip to main content


Axis Therapeutics is a joint venture established in the middle of 2018 by Athenex, Inc. (NASDAQ:ATNX) and Xiangxue Life Sciences Limited, a wholly-owned subsidiary of Xiangxue Pharmaceutical Co., Ltd (Shenzhen Exchange:300147).

Axis Therapeutics in-licensed the worldwide (excluding mainland China) rights for the research, development and commercialization of T-cell receptor-engineered T cells (TCR-T), a cancer immunotherapy technology, from Xiangxue Life Sciences, who developed the novel approach on high-affinity TCR. Xiangxue Life Sciences retains the mainland China rights to the technology.